Uricosuria and crystallization are increasingly recognized risk factors for diabetic tubulopathy.
| INTRODUCTION
Diabetic kidney disease (DKD) remains the leading reason for dialysis in the developed world. 1 While diabetic glomerulopathy has received significant attention from researchers, the determinants of diabetic tubulopathy are less well examined. Compared to glomerular injury, tubular injury is more strongly associated with renal function. 2 Whereas the mechanisms underlying diabetic tubulopathy are still incompletely understood, there is growing evidence that a glucosuria mediated increase in urine uric acid (UA) is a major determinant. 3, 4 Glucosuria is associated with activation of the polyol pathway and consequent increased fructose concentration. 3 Intracellular fructose is further metabolized, generating UA as a byproduct. 3 Individuals with type 1 diabetes (T1D) have more acidic urine than their non-diabetic peers, 4 which may predispose them to UA crystallization and UA-mediated tubulopathy by inflammation and apoptosis of tubular cells. [5] [6] [7] In animal studies, inhibition of UA production protects the kidney from tubular injury, suggesting a causal role for UA in the development of diabetic tubulopathy. 8, 9 Despite compelling evidence implicating UA in the pathogenesis of vascular disease 10 and diabetic tubulopathy, it is unknown whether urinary alkalinization can attenuate UA crystals and tubular injury in the setting of T1D. Accordingly, the goal of this pilot study was to determine the effect of urinary alkalinization with oral sodium bicarbonate (NaHCO 3 ) on UA crystals and markers of tubular injury in adults with T1D. We hypothesized that NaHCO 3 supplementation would raise urine pH and reduce UA crystals in adults with T1D. 
| MATERIALS AND METHODS

| Study design
| Clinical and laboratory measurements
Physical examination measurements including height, weight, body mass index (BMI) and systolic (SBP) and diastolic blood pressure (DBP) were performed at both study visits. All participants were
given standardized questionnaires to obtain demographics, medical history and medication use. After an 8-hour fast, blood and urine were collected, centrifuged and separated. Urine samples were centrifuged at 3900 rpm for 10 minutes at 4 C and urine pH was measured from supernatant using an Accumet basic AB 15 plus pH meter 
| Statistical analysis
Per our power analyses, a sample size of 45 would provide greater than 80% power to detect a change in urine pH of 0.50 following 24 hours of NaHCO 3, assuming an SD of change of 0.42 and a correlation of pre-and post-intervantion urine pH greater than 0.5. 4 Variables were checked for the distributional assumption of normality using normal plots. Variables that were positively skewed were natural log-transformed for the analyses. Paired t-test was used for 
| RESULTS
Clinical characteristics of the study cohort are shown in Table 1 .
Thirty-one percent of participants had evidence of UA crystals prior to therapy. Table S1 shows the characteristics stratified by the presence of UA crystals at baseline.
Oral NaHCO 3 therapy increased urine pH (6.1 AE 0.7 vs 6.5 AE 0.7, P < .0001) ( Figure 1 ) and decreased UA crystals (31.0% vs 6.7%, P = .0045) (Figure 1 ). There was also a modest increase in SBP in response to oral NaHCO 3 , but we observed no significant effects on DBP, HR, eGFR, serum glucose and UA (Table S2 ). As expected, there were no significant differences in serum and urine UA, urine osmolality or eGFR pre-and post-NaHCO 3 (Table S2 ).
The change in urine UA over 24 hours correlated with the change in urine KIM-1 (r: 0.37, P = .01). Participants who experienced an increase in urine UA over 24 hours therefore demonstrated an increase in urine KIM-1 excretion. Furthermore, there was an inverse correlation between change in urine pH over 24 hours and change in urine KIM-1 (r: -0.51, P = .0003). Participants who experienced a decrease in urine pH over 24 hours exhibited an increase in urine KIM-1 excretion. These relationships were not evident with urine NGAL (Table S3) . Conversely, participants who experienced resolution of UA crystals in response to NaHCO 3 experienced a greater decrease in urine NGAL over 24 hours compared to those who had no UA crystals present before or after intervention (Table S4 ).
| DISCUSSION
In this pilot study, almost one third of adults with T1D without CKD had evidence of UA crystals. Oral NaHCO 3 therapy normalized urine pH and decreased the prevalence of UA crystals. Furthermore, an increase in urine pH and a decrease in UA in response to NaHCO 3
were associated with a reduction in KIM-1 excretion, a marker of tubular injury. While this pilot study cannot imply causality between UA crystals and tubular injury, these observations support the hypothesis that urinary alkalinization dissolves UA crystals. NaHCO 3 therefore holds promise as an inexpensive and safe tubule-protective intervention in T1D.
The positive effects of NaHCO 3 supplementation were observed in the absence of any acute effect on serum UA, urine UA or eGFR, suggestive of an independent effect on UA solubility and crystallization. We decided on a total dose of 3900 mg of oral NaHCO 3 a priori for the following reasons: (1) usual adult daily doses range between 1200 and 8000 mg; (2) doses for urinary alkalinization with a goal urine pH of 8.0 tend to be as high as 12 000 mg daily. 11 We did not aim to raise the urine pH above 8.0, but rather, to normalize the relatively acidic urine found in participants with T1D by increasing the urine pH by 0.5 to 1.0. NaHCO 3 supplementation has been shown to preserve renal function in patients with CKD. 12 Experimental data suggest that the benefit of NaHCO 3 may relate to prevention of tubular injury by decreasing cellular β2-microglobulin generation and renal ammoniogenesis. 13, 14 While these data may support our findings, the findings may not be generalizable to our cohort of adults with T1D without CKD. To our knowledge there are no large interventional trials of alkali therapy in adults with early kidney disease. normoglycaemic peers. 4 The UA crystals activate tubular cells via both crystalline and non-crystalline effects, resulting in inflammation, oxidative stress, epithelial-mesenchymal cell transformation and apoptosis with resultant tubulopathy. [5] [6] [7] Limitations to the present study include the small sample size and the non-randomized non-controlled study design. We are also unable to determine whether urinary alkalinization resulted in decreased UA crystals through decreased crystal formation, crystal dissolution or both. Furthermore, we are unable to determine whether the relationships between change in urine UA, KIM-1 and NGAL are independent of urine pH, as urine UA and urine pH are collinear. For these reasons, the data should be viewed as hypothesis generating, and they need to be validated in longer and larger clinical trials. Strengths of the study include strict eligibility criteria and a pre-study diet to control for medication and dietary effects on uricosuria and urine pH. Furthermore, we also directly quantified pre-and post-intervention urine osmolality to control for differences in hydration status.
In summary, UA crystals were common in adults with T1D without CKD, which may predispose them to diabetic tubulopathy. Effect of NaHCO 3 on urine pH and UA crystals in adults with type 1 diabetes. Abbreviation: UUA, urine uric acid scholarly content. K. J. N. helped with study design and reviewed the manuscript for scholarly content. R. J. J. researched, helped with study design and data interpretation, and reviewed the manuscript for scholarly content.
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